GE
GENE.US Genetic Technologies Ltd
- Market cap
- USD 3.71M
- P/E
- -
- P/B
- 3.29x
- ROE
- -656.5%
- Dividend yield
- -
- Fundamental score
- -
Ratios use the latest price and the fiscal year ending Jun 2024.
Is GENE.US undervalued?
Graham numberThe Graham number of Genetic Technologies Ltd cannot be estimated reliably (it needs positive earnings and book value).
Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?
Genetic Technologies Ltd fundamental analysis
No fundamental analysis for Genetic Technologies Ltd yet.
Genetic Technologies Ltd stock price
Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.
About Genetic Technologies Ltd
Genetic Technologies Limited, a molecular diagnostics company, engages in the provision of predictive genetic testing and risk assessment tools to help physicians manage people's health in the America, Canada, Europe, the Middle East, Africa, Latin America, and the Asia Pacific. The company operates through EasyDNA, AffinityDNA, and GeneType/Corporate segments. It offers BREVAGenplus, a clinically validated risk assessment test for non-hereditary breast cancer. The company a…
Full company profileGenetic Technologies Ltd financial statements
Genetic Technologies Ltd annual financial statements (AUD; K = thousand, M = million, B = billion, T = trillion)
| Item | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|---|---|---|---|---|
| Income Statement | ||||||||||
| Revenue | 2.01M | 825K | 519K | 189K | 25.4K | 9.86K | 121K | 6.79M | 10.3M | 7.66M |
| Gross Profit | 685K | 81.5K | 26.1K | -111K | -251K | -242K | -240K | 6.47M | 6.01M | 3.90M |
| Operating Income | -9.87M | -8.49M | -8.17M | -6.40M | -6.00M | -6.08M | -7.06M | -7.54M | -10.4M | -12.2M |
| EBITDA | -8.42M | -8.10M | -7.80M | -5.46M | -6.00M | -6.08M | -7.06M | -7.20M | -11.2M | -11.4M |
| Net Income | -8.81M | -8.46M | -8.40M | -5.46M | -6.83M | -6.30M | -7.21M | -7.13M | -11.8M | -12.0M |
| EPS | -25 | -15 | -12 | -6.73 | -7.26 | -4.55 | -2.53 | -2.32 | -3.48 | -2.61 |
| Balance Sheet | ||||||||||
| Total Assets | 20.7M | 13.3M | 12.1M | 6.17M | 3.27M | 15.6M | 23.0M | 20.8M | 14.9M | 6.19M |
| Total Liabilities | 1.76M | 1.41M | 1.53M | 1.45M | 1.49M | 1.64M | 1.44M | 4.37M | 3.69M | 4.36M |
| Shareholders' Equity | 19.0M | 11.9M | 10.6M | 4.71M | 1.77M | 14.0M | 21.5M | 16.4M | 11.2M | 1.83M |
| Cash & Short-term Investments | 18.3M | 11.2M | 11.0M | 5.49M | 2.19M | 14.2M | 20.9M | 11.7M | 7.87M | 1.02M |
| Total Debt | 25.0K | 0.00 | 0.00 | 0.00 | 0.00 | 482K | 204K | 653K | 533K | 875K |
| Cash Flow | ||||||||||
| Operating Cash Flow | -9.69M | -7.73M | -6.81M | -5.64M | -6.07M | -5.71M | -6.30M | -5.66M | -9.72M | -9.68M |
| Capital Expenditure | 193K | 303K | 235K | 2.39K | 50.3K | 38.1K | 642K | 96.8K | 17.6K | 33.0K |
| Free Cash Flow | -9.88M | -8.03M | -7.05M | -5.64M | -6.12M | -5.75M | -6.94M | -5.76M | -9.74M | -9.71M |
| Ratios | ||||||||||
| ROE | -46.5% | -71.2% | -79.4% | -116.0% | -385.8% | -45.1% | -33.5% | -43.4% | -105.3% | -656.5% |
| ROA | -42.5% | -63.7% | -69.4% | -88.6% | -209.3% | -40.3% | -31.4% | -34.3% | -79.1% | -194.2% |
| Net Profit Margin | -437.9% | -1,025.8% | -1,620.8% | -2,887.1% | -26,855.4% | -63,909.9% | -5,979.0% | -104.9% | -113.6% | -156.8% |
| Debt to Equity | 0.00x | 0.00x | 0.00x | 0.00x | 0.00x | 0.03x | 0.01x | 0.04x | 0.05x | 0.48x |
What these items mean
- Revenue
- Total sales of goods and services in the period.
- Gross Profit
- Revenue minus the direct cost of producing what was sold.
- Operating Income
- Profit from the core business after operating expenses.
- EBITDA
- Earnings before interest, taxes, depreciation and amortization.
- Net Income
- Profit left for shareholders after all expenses, interest and taxes.
- EPS
- Net income divided by shares outstanding.
- Total Assets
- Everything the company owns.
- Total Liabilities
- Everything the company owes.
- Shareholders' Equity
- Assets minus liabilities: the book value that belongs to shareholders.
- Cash & Short-term Investments
- Cash and investments that can be turned into cash quickly.
- Total Debt
- Short and long-term borrowings.
- Operating Cash Flow
- Cash generated by the core business.
- Capital Expenditure
- Cash spent on property, plant and equipment.
- Free Cash Flow
- Operating cash flow minus capital expenditure: cash left for dividends, buybacks or debt repayment.
- ROE
- Return on equity: net income divided by shareholders' equity.
- ROA
- Return on assets: net income divided by total assets.
- Net Profit Margin
- Net income as a share of revenue.
- Debt to Equity
- Total debt divided by shareholders' equity.
Genetic Technologies Ltd dividends
Genetic Technologies Ltd has not paid dividends in the last 10 fiscal years.
Last stock split: 1:5 on Dec 14, 2023.
Who owns Genetic Technologies Ltd
- Insiders 0.00%
- Institutions 1.87%
- Public & others 98.13%
- Shares outstanding 4.85M
- Free float 27.9M
Top funds holding GENE.US
| Holder | Shares | % of shares | Change | As of |
|---|---|---|---|---|
| Fidelity Nasdaq Composite Index | 502.00 | 0.01% | 0.00% | Jul 2026 |
Top institutions holding GENE.US
| Holder | Shares | % of shares | Change | As of |
|---|---|---|---|---|
| Rhumbline Advisers | 2.65K | 0.07% | 0.00% | Mar 2026 |
Genetic Technologies Ltd company profile
- Company name
- Genetic Technologies Ltd
- Ticker
- GENE.US
- Exchange
- USA Stocks
- Listed since
- Sep 2, 2005
- Sector
- Healthcare
- Industry
- Life Sciences Tools & Services
- Employees
- 55
- Fiscal year end
- June
- Address
- 321 Chapel Street, Prahran, VIC, Australia, 3181
- Phone
- 61 3 8412 7000
- Website
- genetype.com
About Genetic Technologies Ltd
Genetic Technologies Limited, a molecular diagnostics company, engages in the provision of predictive genetic testing and risk assessment tools to help physicians manage people's health in the America, Canada, Europe, the Middle East, Africa, Latin America, and the Asia Pacific. The company operates through EasyDNA, AffinityDNA, and GeneType/Corporate segments. It offers BREVAGenplus, a clinically validated risk assessment test for non-hereditary breast cancer. The company also markets BREVAGenplus to healthcare professionals in breast health care and imaging centers, as well as to obstetricians/gynecologists and breast cancer risk assessment specialists, such as breast surgeons. In addition, it offers various cancer risk assessment tests under the GeneType for Colorectal Cancer and GeneType for Breast Cancer brand names; and develops other risk assessment tests across a range of diseases, which include colorectal cancer, ovarian cancer, prostate cancer, coronary artery, type 2 diabetes, pancreatic cancer, melanoma, and atrial fibrillation. Further, it offers genetic testing services, including medical, animal, forensic, and plant testing. It has research and collaboration agreements with the University of Melbourne for the development and commercialization of a novel colorectal cancer risk assessment test; Memorial Sloan Kettering Cancer Center of New York and University of Cambridge, that assess the conflict among BRCA mutation carriers considering preventive surgery; and research collaboration with Harvard University, Ohio State University, and Washington University. The company was incorporated in 1987 and is headquartered in Prahran, Australia.
Genetic Technologies Ltd management
4- Mr. Kevin CamilleriChief Executive Officer of EasyDNA · born 1977
- Mr. Mark ZiirsenCFO & Company Secretary · born 1963
- Mr. Paul Keith Mathieson Viney B. Bus, FCI, FCPA, FGIAConsultant
- Dr. Erika Spaeth Ph.D.Director of Clinical & Scientific Affairs